Particle Therapy Market Size - Share Outlook, Growth Analysis Report and Forecast Trends 2026-2030

Particle therapy is an advanced form of external beam radiotherapy in which protons or heavy ions such as carbon are used to deliver a highly conformal dose to tumors while sparing surrounding healthy tissue. The market encompasses treatment planning software, particle accelerators (synchrotrons and cyclotrons), beam delivery systems, and the operation of treatment facilities. The market is dominated by proton therapy, with carbon-ion therapy representing a smaller but growing segment.

• •Valued at approximately USD 1.68 billion in 2025, expanding at a CAGR of about 8.45%.
• •Includes equipment, treatment planning systems, and clinical services tied to particle beam facilities.
• •Used primarily for pediatric cancers, head and neck tumors, prostate cancer, and other radiation-sensitive indications.

Rising global cancer incidence is creating sustained demand for more precise radiotherapy modalities with fewer long-term side effects. Reimbursement expansion, particularly in the United States, Europe, and parts of Asia, is improving patient access to proton and carbon-ion therapy. Continued reductions in system footprint and cost through compact accelerators, such as single-room proton systems, are lowering barriers to entry for hospitals.

• •Growing cancer burden, especially in aging populations across North America, Europe, and East Asia.
• •Favorable clinical evidence and broader insurance reimbursement for proton therapy indications.
• •Technology advances including compact and superconducting accelerators that reduce facility size and capital cost.

The market is segmented by therapy type (proton therapy and carbon-ion therapy), by component (accelerators, beam delivery, treatment planning, and services), and by cancer indication. North America leads in installed systems and revenue, supported by strong reimbursement frameworks and significant private capital investment. Europe and the Asia-Pacific region are the fastest-growing markets due to large-scale public investments in new centers.

• •Proton therapy accounts for the majority of revenue; carbon-ion therapy is concentrated in Japan, Germany, China, and a small number of other facilities worldwide.
• •North America holds the largest share, followed by Europe, with Asia-Pacific showing the fastest growth as China builds the largest expansion pipeline.
• •Pediatric oncology, head and neck cancers, and prostate cancer remain the most actively treated indications globally.

What are the recent trends and outlook?

The market outlook points to continued mid- to high-single-digit growth as more compact systems come online and as clinical evidence for carbon-ion therapy matures. Hypofractionation protocols, FLASH-style ultra-high-dose-rate research, and AI-driven treatment planning are emerging as the next performance and efficiency frontiers. Long-term, the industry's main constraint is capital cost and capacity, which new compact systems and expanded payer coverage are progressively addressing.

• •Compact single-room proton systems are expanding adoption among mid-sized hospitals in the United States, Europe, and Asia.
• •Carbon-ion therapy capacity is rising in China and other Asian markets following Japan's established leadership.
• •Integration with AI-based planning, image-guidance, and adaptive therapy is expected to improve throughput and reduce costs per treatment over time.